Article Details
Retrieved on: 2025-05-23 07:51:16
Tags for this article:
Click the tags to see associated articles and topics
Summary
Zealand Pharma, a biotechnology firm, is evaluated within the stock market context. Despite a negative P/E ratio and recent stock price decline, its product Dasiglucagon highlights growth potential. Analysts have mixed views on its EPS outlook.
Article found on: www.defenseworld.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here